Evaluation of eight plasma proteins as candidate blood-based biomarkers for malignant gliomas

Cancer Investigation

Volumn 32, Issue 8, 2014, Pages 423-429

  Lange, Ryan P ^a   Everett, Allen ^a,b   Dulloor, Pratima ^a,b   Korley, Frederick K ^a,b   Bettegowda, Chetan ^a,b,c   Blair, Cherie ^a,c   Grossman, Stuart A ^a,b,c   Holdhoff, Matthias ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Pediatrics ^*  (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Brain Tumors; Cancer Biomarkers; Circulating Biomarkers; Glioma; Proteins

Indexed keywords

BETA SYNUCLEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CELL ADHESION MOLECULE; GLIAL FIBRILLARY ACIDIC PROTEIN; INTRACELLULAR ADHESION MOLECULE 5; METALLOTHIONEIN III; NEUROGRANIN; NEURON SPECIFIC ENOLASE; PLASMA PROTEIN; PROTEIN S 100; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GRADING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLIOMA; GLIOSARCOMA; HUMAN; MALE; PRESCHOOL CHILD; SCHOOL CHILD; BLOOD; BRAIN TUMOR; METABOLISM; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PROTEINS; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84907062215     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2014.933237     Document Type: Article

References (59)

1. Brandsma D, Stalpers L, Taal W, Sminia P, van den bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008;9:453-461.
2. Macdonald DR, Cascino TL, Schold, SC, Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
3. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas, response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-1972.
4. PartinA,Yoo J, CarterH, PearsonJD,ChanDW, EpsteinJI,Walsh PC.The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-114.
5. Duffy M, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O. Tumour markers in colorectal cancer, European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007;43:1348-60.
6. Bruix J, Sherman M. Managment of Hepatocellular carcinoma. Hepatology 2005;42:1205-1236.
7. Holdhoff M, Yovino SG, Boadu O, Grossman SA. Bloodbased biomarkers for malignant gliomas. J Neurooncol 2013;113:345-352.
8. Ilhan-Mutlu A, Wagner L, Widhalm G, Wohrer A, Bartsch S, Czech T, Heinzl H, Leutmezer F, Prayer D, Marosi C, Base W, Preusser M. Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurg Rev 2012;36:45-55.
9. Brommeland T, Rosengren L, Fridlund S, Hennig R, Isaksen V. Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Acta Neurol Scand 2007;116:380-384.
10. Jung CS, Foerch C, Schanzer A, Heck A, Plate KH, Seifert V, Steinmetz H, Raabe A, Sitzer M. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 2007;130:3336-3341.
11. Lyubimova NV, TomsMG, Popova EE, Bondarenko YV, Krat VB, Kushlinskii NE. Neurospecific proteins in the serum of patients with brain tumors. Bull Exp Biol Med 2011;150:732-734.
12. Schiff L, Hadker N, Weiser S, Rausch C. A literature reviewof the feasibility of glial fibrillary acidic protein as a biomarker for stroke and traumatic brain injury. Mol Diagn Ther 2012;16:79-92.
13. Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res 2000;25:1439-1451.
14. Ilhan-Mutlu A, Berghoff AS, Furtner J, Dieckmann K, Slavc I, Czech T, Marosi C, Wagner L, Preusser M. High plasma-GFAP levels in metastatic myxopapillary ependymoma. J Neurooncol 2013;113:359-363.
15. Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, Hansson O,Minthon L, Zetterberg H, Blennow K. Neurogranin in cerebrospinal fluid as amarker of synaptic degeneration in Alzheimer's disease. Brain Res 2010;1362:13-22.
16. Diez-Guerra FJ. Neurogranin., a link between calcium/ calmodulin and protein kinase C signaling in synaptic plasticity. IUBMB Life 2010;62:597-606.
17. Rose EJ, Morris DW, Fahey C, Robertson IH, Greene C, O'Doherty J, Newell FN, Garavan H, McGrath J, Bokde A, Tropea D, Gill M, Corvin AP, Donohoe G. The effect of the neurogranin schizophrenia risk variant rs12807809 on brain structure and function. Twin Res Hum Genet 2012;15:296-303.
18. Lin B, Madan A, Yoon JG, Fang X, Yan X, Kim TK, Hwang D, Hood L, Foltz G. Massively parallel signature sequencing and bioinformatics analysis identifies up-regulation of TGFBI and SOX4 in human glioblastoma. PLoS One 2010;5:e10210.
19. Frota ER, Rodrigues DH, Donadi EA, Brum DG, Maciel DR, Teixeira AL. Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse. Neurosci Lett 2009;460:130-132.
20. Di Lazzaro V, Profice P, Pilato F, Dileone M, Florio L, Tonali PA, Angelucci F. BDNF plasma levels in acute stroke. Neurosci Lett 2007;422:128-130.
21. Saruta J, Fujino K, To M, Tsukinoki K. Expression and localization of brain-derived neurotrophic factor (BDNF) mRNA and protein in human submandibular gland. Acta Histochem Cytochem 2012;45:211-218.
22. Xiong J, Zhou L, Yang M, Lim Y, Zhu YH, Fu DL, Li ZW, Zhong JH, Xiao ZC, Zhou XF. ProBDNF and its receptors are upregulated in glioma and inhibit the growth of glioma cells in vitro. Neuro Oncol 2013;15:990-1007.
23. Yousuf S, Atif F, Sayeed I, Wang J, Stein DG. Post-stroke infections exacerbate ischemic brain injury in middle-aged rats, immunomodulation and neuroprotection by progesterone. Neuroscience 2013;239:92-102.
24. MoritaK, LeeMS,Her S. Possible relation of hemin-inducedHO-1 expression to the upregulation of VEGF and BDNFmRNAlevels in rat C6 glioma cells. J Mol Neurosci 2009;38:31-40.
25. Xie Q, Thompson R, Hardy K, DeCamp L, Berghuis B, Sigler R, Knudsen B, Cottingham S, Zhao P, Dykema K, Cao B, Resau J, Hay R, Vande Woude GF. A highly invasive human glioblastoma pre-clinical model for testing therapeutics. J Transl Med 2008;6:77-5876-6-77.
26. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM. Expression and function of TRK-B and BDNF in human neuroblastomas.Mol Cell Biol 1994;14:759-767.
27. Jansen JF, Vlooswijk MC, de Baets MH, de Krom MC, Rieckmann P, Backes WH, Aldenkamp AP, SEGAED Study Group. Cognitive fMRI and soluble telencephalin assessment in patients with localization-related epilepsy. Acta Neurol Scand 2008;118:232-239.
28. Borusiak P, Gerner P, Brandt C, Kilgannon P, Rieckmann P. Soluble Telencephalin in the serum of children after febrile seizures. J Neurol 2005;252:493-494.
29. Gahmberg CG, Tian L, Ning L, Nyman-Huttunen H. ICAM-5-a novel two-facetted adhesion molecule in the mammalian brain. Immunol Lett 2008;117:131-135.
30. Lindsberg PJ, Launes J, Tian L, Valimaa H, Subramanian V, Siren J, Hokkanen L, Hypia T, Caprpen O, Gahmenberg CG. Release of soluble ICAM-5, a neuronal adhesion molecule, in acute encephalitis. Neurology 2002;58:446-451.
31. Tian L, Lappalainen J, AuteroM, Hanninen S, RauvalaH,Gahmberg CG. Shedded neuronal ICAM-5 suppresses T-cell activation. Blood 2008;111:3615-3625.
32. Howells C,West AK, Chung RS. Neuronal growth-inhibitory factor (metallothionein-3), evaluation of the biological function of growth-inhibitory factor in the injured and neurodegenerative brain. FEBS J 2010;277: 2931-2939.
33. Nordberg M. Metallothioneins, historical review and state of knowledge. Talanta 1998;46:243-254.
34. Vasak M, Meloni G. Chemistry and biology of mammalian metallothioneins. J Biol Inorg Chem 2011;16:1067-1078.
35. Werynska B, Pula B,Muszczynska-Bernhard B, Gomulkiewicz A, Jethon A, Podhorska-OkolowM, Jankowska R, Dziegiel P. Expression of metallothionein-III in patients with non-small cell lung cancer. Anticancer Res 2013;33:965-974.
36. Yanagitani S, Miyazaki H, Nakahashi Y, Kuno K, Ueno Y, Matsushita M, Naitoh Y, Taketani S, Inoue K. Ischemia induces metallothionein III expression in neurons of rat brain. Life Sci 1999;64:707-715.
37. Wei H, Desouki MM, Lin S, Xiao D, Franklin RB, Feng P. Differential expression ofmetallothioneins (MTs) 1, 2, and 3 in response to zinc treatment in human prostate normal and malignant cells and tissues. Mol Cancer 2008;7:7.
38. Luo Y, Xu Y, Bao Q, Ding Z, Zhu C,Huang ZX, Tan X.Themolecular mechanism for human metallothionein-3 to protect against the neuronal cytotoxicity of Abeta(1-42) with Cu ions. J Biol Inorg Chem 2013;18: 39-47.
39. Surguchov A. Synucleins, are they two-edged swords? J Neurosci Res 2013;91:161-166.
40. Fung KM, Rorke LB, Giasson B, Lee VM, Trojanowski JQ. Expression of alpha-, beta-, and gamma-synuclein in glial tumors and medulloblastomas. Acta Neuropathol 2003;106:167-175.
41. Fujita M, Sekigawa A, Sekiyama K, Sugama S, Hasimoto M. Neurotoxic conversion of beta-synuclein, a novel approach to generate a transgenic mouse model of synucleinopathies? J Neurol 2009;256(Suppl 3):286-292.
42. George JM.The synucleins. Genome Biol 2002;3:REVIEWS3002.
43. Ahmad M, Attoub S, Singh MN, Martin FL, El-Agnaf OM. Gamma-synuclein and the progression of cancer. FASEB J 2007;21:3419-3430.
44. Fagnart OC, Sindic CJ, Laterre C. Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. Clin Chem 1988;34:1387-1391.
45. Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ, Geczy CL. Functions of S100 proteins. Curr Mol Med 2013;13: 24-57.
46. Kanner AA, Marchi N, Fazio V, Mayberg MR, Koltz MT, Siomin V, Stevens GH, Masaryk T, Aumayr B, Vogelbaum MA, Barnett GH, Janigro D. Serum S100beta, a noninvasive marker of blood-brain barrier function and brain lesions. Cancer 2003;97:2806-2813.
47. Vos PE, Jacobs B, Andriessen TM, Lamers KJ, Borm GF, Beems T, Edwards M, Rosmalen CF, Vissers JL. GFAP and S100B are biomarkers of traumatic brain injury, an observational cohort study. Neurology 2010;75:1786-1793.
48. Gartner W, Ilhan A, Neziri D, Base W, Weissel M, Wohrer A, Heinzl H, Waldhor T, Wagner L, Preusser M. Elevated blood markers 1 year before manifestation of malignant glioma. Neuro Oncol 2010;12:1004-1008.
49. Mercier E, Boutin A, Lauzier F, Fergusson DA, Simard JF, Zarychanski R, Moore L, McIntyre LA, Archambault P, Lamontagne F, Legare F, Randell E,Nadeau L, Rousseau F, Turgeon AF. Predictive value of S-100beta protein for prognosis in patients with moderate and severe traumatic brain injury, systematic review and meta-analysis. BMJ 2013;346:f1757.
50. Bloomfield SM, McKinney J, Smith L, Brisman J. Reliability of S100B in predicting severity of central nervous system injury. Neurocrit Care 2007;6:121-138.
51. Kleindienst A, Ross Bullock M. A critical analysis of the role of the neurotrophic protein S100B in acute brain injury. J Neurotrauma 2006;23:1185-1200.
52. Stein DM, Lindell AL, Murdock KR, Kufera JA, Menaker J, Bochicchio GV, Aarabi B, Scalea TM. Use of serum biomarkers to predict cerebral hypoxia after severe traumatic brain injury. J Neurotrauma 2012;29:1140-1149.
53. Yan T, Skaftnesmo KO, Leiss L, Sleire L, Wang J, Li X, Enger PO. Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide. BMC Cancer 2011;11:524.
54. Bohmer AE,Oses JP, SchmidtAP, PeronCS,Krebs CL,Oppitz PP, D'Avila TT, Souza DO, Portela LV, Stefani MA. Neuron-specific enolase, S100B, and glial fibrillary acidic protein levels as outcome predictors in patients with severe traumatic brain injury. Neurosurgery 2011;68:1624-30, discussion 1630-1.
55. Husain H, Savage W, Grossman SA, Ye X, Burger PC, Everett A, Bettegowda C, Diaz LA, Jr., Blair C, Romans KE, Holdhoff M. Pre-and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas. J Neurooncol 2012;109:123-127.
56. LiWB, Tang K, Chen Q, Li S, Qiu XG, Li SW, Jiang T. MRI manifestions correlate with survival of glioblastoma multiforme patients. Cancer Biol Med 2012;9:120-123.
57. Dabrowski W, Rzecki Z, Czajkowski M, Pilat J, Wacinski P, Kotlinska E, SztankeM, SztankeK, StazkaK, PasternakK.Volatile anesthetics reduce biochemical markers of brain injury and brain magnesium disorders in patients undergoing coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2012;26:395-402.
58. Vutskits L, Lysakowski C, Czarnetzki C, Jenny B, copin JC, Tramer MR. Plasma concentrations of brain-derived neurotrophic factor in patients undergoing minor surgery, a randomized controlled trial. Neurochem Res 2008;33:1325-1331.
59. Wijeyaratne SM, Collins MA, Barth JH, Gough MJ. Jugular venous neurone specific enolase (NSE) increases following carotid endarterectomy under general, but not local, anaesthesia. Eur J Vasc Endovasc Surg 2009;38:262-266.